David D. Ørsted

4.2k total citations · 1 hit paper
32 papers, 2.4k citations indexed

About

David D. Ørsted is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David D. Ørsted has authored 32 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Endocrinology, Diabetes and Metabolism and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David D. Ørsted's work include Diabetes Treatment and Management (11 papers), Metabolism, Diabetes, and Cancer (8 papers) and Prostate Cancer Treatment and Research (7 papers). David D. Ørsted is often cited by papers focused on Diabetes Treatment and Management (11 papers), Metabolism, Diabetes, and Cancer (8 papers) and Prostate Cancer Treatment and Research (7 papers). David D. Ørsted collaborates with scholars based in Denmark, United States and Germany. David D. Ørsted's co-authors include Børge G. Nordestgaard, Marie Kim Wium‐Andersen, Stig E. Bojesen, John B. Buse, Bernard Zinman, Neil R Poulter, Søren Rasmussen, Johannes F.E. Mann, Steven P. Marso and Karen Tornøe and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Experimental Medicine.

In The Last Decade

David D. Ørsted

32 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Liraglutide and Renal Outcomes in Type 2 Diabetes

2017 859 citations Johannes F.E. Mann, David D. Ørsted et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David D. Ørsted Denmark	20	1.1k	610	444	394	292	32	2.4k
Man K. Chan United Kingdom	21	563 0.5×	519 0.9×	509 1.1×	411 1.0×	123 0.4×	68	2.4k
Marie Pigeyre France	30	927 0.8×	619 1.0×	975 2.2×	219 0.6×	92 0.3×	89	3.5k
Ian C. Wilson United States	26	415 0.4×	293 0.5×	570 1.3×	110 0.3×	222 0.8×	56	2.1k
Tracy Dew United Kingdom	24	152 0.1×	292 0.5×	470 1.1×	295 0.7×	104 0.4×	51	1.9k
C.R.W. Edwards United Kingdom	30	1.9k 1.6×	616 1.0×	624 1.4×	46 0.1×	188 0.6×	75	4.0k
D. Haack Germany	20	612 0.5×	246 0.4×	165 0.4×	78 0.2×	115 0.4×	51	1.5k
Daniel Kopf Germany	21	397 0.3×	160 0.3×	202 0.5×	121 0.3×	78 0.3×	77	1.3k
Edoardo Guastamacchia Italy	26	993 0.9×	372 0.6×	303 0.7×	29 0.1×	166 0.6×	123	2.2k
Symen Ligthart Netherlands	23	455 0.4×	339 0.6×	125 0.3×	119 0.3×	53 0.2×	29	1.5k
Paul M. Copeland United States	25	761 0.7×	254 0.4×	503 1.1×	158 0.4×	191 0.7×	51	2.7k

Countries citing papers authored by David D. Ørsted

Since Specialization

Citations

This map shows the geographic impact of David D. Ørsted's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David D. Ørsted with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David D. Ørsted more than expected).

Fields of papers citing papers by David D. Ørsted

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David D. Ørsted. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David D. Ørsted. The network helps show where David D. Ørsted may publish in the future.

Co-authorship network of co-authors of David D. Ørsted

This figure shows the co-authorship network connecting the top 25 collaborators of David D. Ørsted. A scholar is included among the top collaborators of David D. Ørsted based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David D. Ørsted. David D. Ørsted is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zinman, Bernard, Michael A. Nauck, Heidrun Bosch‐Traberg, et al.. (2018). Liraglutide and Glycaemic Outcomes in the LEADER Trial. Diabetes Therapy. 9(6). 2383–2392. 35 indexed citations

Steinberg, William M., et al.. (2017). Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial. Diabetes Care. 40(7). 966–972. 67 indexed citations

Mann, Johannes F.E., David D. Ørsted, Kirstine Brown‐Frandsen, et al.. (2017). Liraglutide and Renal Outcomes in Type 2 Diabetes. New England Journal of Medicine. 377(9). 839–848. 859 indexed citations breakdown →

Davidson, Jaime A., David D. Ørsted, & Carlos Campos. (2016). Efficacy and safety of liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue, in L atino/ H ispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials. Diabetes Obesity and Metabolism. 18(7). 725–728. 8 indexed citations

Rutten, Guy E.H.M., Cees J. Tack, Thomas R. Pieber, et al.. (2016). LEADER 7: cardiovascular risk profiles of US and European participants in the LEADER diabetes trial differ. Diabetology & Metabolic Syndrome. 8(1). 37–37. 10 indexed citations

Satman, İlhan, Rosângela Réa, Mats Eriksson, et al.. (2016). LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. Journal of Diabetes and its Complications. 30(8). 1631–1639. 5 indexed citations

Wium‐Andersen, Marie Kim, David D. Ørsted, Line Rode, Stig E. Bojesen, & Børge G. Nordestgaard. (2016). Telomere length and depression: Prospective cohort study and Mendelian randomisation study in 67 306 individuals. The British Journal of Psychiatry. 210(1). 31–38. 28 indexed citations

Wium‐Andersen, Marie Kim, David D. Ørsted, & Børge G. Nordestgaard. (2015). Elevated C-reactive protein and late-onset bipolar disorder in 78 809 individuals from the general population. The British Journal of Psychiatry. 208(2). 138–145. 50 indexed citations

Wium‐Andersen, Marie Kim, David D. Ørsted, & Børge G. Nordestgaard. (2015). Tobacco smoking is causally associated with antipsychotic medication use and schizophrenia, but not with antidepressant medication use or depression. International Journal of Epidemiology. 44(2). 566–577. 44 indexed citations

10.

Scholten, Bernt Johan von, David D. Ørsted, Anne Louise Svendsen, Frederik Persson, & Peter Rossing. (2015). The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. Journal of Diabetes and its Complications. 29(8). 1146–1151. 9 indexed citations

11.

Ørsted, David D., Børge G. Nordestgaard, & Stig E. Bojesen. (2014). Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Annals of Oncology. 25(3). 712–718. 37 indexed citations

12.

Wium‐Andersen, Marie Kim, David D. Ørsted, & Børge G. Nordestgaard. (2013). Elevated C-Reactive Protein Associated With Late- and Very-Late-Onset Schizophrenia in the General Population: A Prospective Study. Schizophrenia Bulletin. 40(5). 1117–1127. 66 indexed citations

13.

Wium‐Andersen, Marie Kim, David D. Ørsted, & Børge G. Nordestgaard. (2013). Elevated C-Reactive Protein, Depression, Somatic Diseases, and All-Cause Mortality: A Mendelian Randomization Study. Biological Psychiatry. 76(3). 249–257. 77 indexed citations

14.

Ørsted, David D., Stig E. Bojesen, Pia R. Kamstrup, & Børge G. Nordestgaard. (2013). Long-term Prostate-specific Antigen Velocity in Improved Classification of Prostate Cancer Risk and Mortality. European Urology. 64(3). 384–393. 20 indexed citations

15.

Wium‐Andersen, Marie Kim, David D. Ørsted, Yan V. Sun, & Børge G. Nordestgaard. (2012). Elevated C-Reactive Protein Levels, Psychological Distress, and Depression in 73 131 Individuals. JAMA Psychiatry. 70(2). 176–176. 377 indexed citations

16.

Wium‐Andersen, Marie Kim, David D. Ørsted, & Børge G. Nordestgaard. (2012). Elevated plasma fibrinogen, psychological distress, antidepressant use, and hospitalization with depression: Two large population-based studies. Psychoneuroendocrinology. 38(5). 638–647. 32 indexed citations

17.

Ørsted, David D. & Stig E. Bojesen. (2012). The link between benign prostatic hyperplasia and prostate cancer. Nature Reviews Urology. 10(1). 49–54. 128 indexed citations

18.

Ørsted, David D., Børge G. Nordestgaard, Gorm Boje Jensen, Peter Schnohr, & Stig E. Bojesen. (2011). Prostate-Specific Antigen and Long-Term Prediction of Prostate Cancer Incidence and Mortality in the General Population. European Urology. 61(5). 865–874. 34 indexed citations

19.

Ørsted, David D., Stig E. Bojesen, Anne Tybjærg‐Hansen, & Børge G. Nordestgaard. (2007). Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. The Journal of Experimental Medicine. 204(6). 1295–1301. 103 indexed citations

20.

Ørsted, David D., Stig E. Bojesen, Anne Tybjærg‐Hansen, & Børge G. Nordestgaard. (2007). Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. The Journal of Cell Biology. 177(5). i14–i14. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact